Home » Stocks » LQDA

Liquidia Technologies, Inc. (LQDA)

Stock Price: $2.90 USD -0.09 (-3.01%)
Updated Jan 27, 2021 2:02 PM EST - Market open
Market Cap 129.48M
Revenue (ttm) n/a
Net Income (ttm) -58.17M
Shares Out 37.76M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $2.90
Previous Close $2.99
Change ($) -0.09
Change (%) -3.01%
Day's Open 2.98
Day's Range 2.73 - 2.98
Day's Volume 2,197,036
52-Week Range 2.60 - 3.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.

Business Wire - 3 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.

Business Wire - 3 weeks ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Liquidia Corporation (NASDA...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 20, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA).   Such investors ...

GlobeNewsWire - 1 month ago

RESEARCH TRIANGLE PARK, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a direc...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA).   Such investors ...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). Such investors ar...

GlobeNewsWire - 1 month ago

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective i...

Zacks Investment Research - 2 months ago

The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form

PRNewsWire - 2 months ago

NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are ad...

GlobeNewsWire - 2 months ago

CRL does not cite need for additional clinical studies

GlobeNewsWire - 2 months ago

Merger Reinforc es Company's Commitment to Patients with PAH

GlobeNewsWire - 2 months ago

Stockholders Approve RareGen Acquisition

GlobeNewsWire - 2 months ago

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and comme...

Seeking Alpha - 2 months ago

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

- Raised $75 M illion through Underwritten Public Offering - Bolstered and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to...

GlobeNewsWire - 2 months ago

Company Determines Unsolicited Offer does not Constitute Superior Proposal

GlobeNewsWire - 2 months ago

Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET

GlobeNewsWire - 2 months ago

Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET

Seeking Alpha - 3 months ago

Lead candidate LIQ861 has shown an equivalent safety profile to UTHR's Tyvaso, and is also a bit easier to use.

GlobeNewsWire - 3 months ago

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and comme...

GlobeNewsWire - 3 months ago

PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso® PTAB Institutes Inter Partes Review Proceeding Against...

GlobeNewsWire - 3 months ago

Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical...

GlobeNewsWire - 4 months ago

Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020

GlobeNewsWire - 4 months ago

RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

GlobeNewsWire - 5 months ago

Steven Bariahtaris Appointed Interim Chief Financial Officer Steven Bariahtaris Appointed Interim Chief Financial Officer

Seeking Alpha - 5 months ago

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

GlobeNewsWire - 5 months ago

New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (Qo...

GlobeNewsWire - 5 months ago

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and comm...

GlobeNewsWire - 6 months ago

RESEARCH TRIANGLE PARK, N.C., July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

InvestorPlace - 6 months ago

When Wall Street ignores micro-cap stocks, it creates deep value opportunities, if a company is able to turn things around against fortune.

Other stocks mentioned: ARLO, ITRN, RADA, SWIR, VERI, XBIT
24/7 Wall Street - 6 months ago

Liquidia Technologies Inc. (NASDAQ: LQDA) has seen its share of news after an acquisition and a recent stock sale.

GlobeNewsWire - 6 months ago

RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

Forbes - 6 months ago

Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.

Other stocks mentioned: BCRX, FLNT, GRUB, MNKD
GlobeNewsWire - 6 months ago

RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

GlobeNewsWire - 6 months ago

RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

GlobeNewsWire - 6 months ago

RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

Forbes - 7 months ago

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify severa...

Other stocks mentioned: AGLE, DVAX, PHAS, SEEL
Forbes - 7 months ago

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several ...

Other stocks mentioned: BLNK, NAVB, SVRA
GlobeNewsWire - 7 months ago

RESEARCH TRIANGLE PARK, N.C., June 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...

Zacks Investment Research - 8 months ago

Liquidia Technologies (LQDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and comm...

Seeking Alpha - 8 months ago

Liquidia Technologies' (LQDA) CEO Neal Fowler on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and co...

GlobeNewsWire - 9 months ago

RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and co...

Seeking Alpha - 10 months ago

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 10 months ago

Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Liquidia.

About LQDA

Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, a... [Read more...]

Industry
Biotechnology
IPO Date
Jul 26, 2018
Stock Exchange
NASDAQ
Ticker Symbol
LQDA
Full Company Profile

Financial Performance

In 2019, LQDA's revenue was $8.07 million, an increase of 198.20% compared to the previous year's $2.71 million. Losses were -$47.58 million, -10.45% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is 5.20, which is an increase of 79.31% from the latest price.

Price Target
$5.20
(79.31% upside)
Analyst Consensus: Buy